| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Takeda ((TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Wel...
Takeda ((TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating...
− Approval Based on Results from Positive, Global, Phase 3 FRESCO-2 Trial− FRUZAQLA (fruquintinib) is the First Novel Targeted ...
HyQvia®, which may be administered at home, will provide children and adolescents living with immunodeficiencies with a new tre...
Favorable Findings from the Longest Public Clinical Study in CIDP Support HYQVIA as an Effective Long-Term Treatment Option for...
Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In ...
Takeda Pharmaceutical released topline data from its Phase 3 studies, SKYLINE and SKYWAY, on Soticlestat for refractory Dravet ...
